Quest Diagnostics Inc (DGX) stock
DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 12/3011% above fair value
$262.21+2.61 (+1.01%)
Close on Nov 16, 2026Market cap $28.85BP/E 26.1Yield –
Quest Diagnostics r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Quest Diagnostics
Quest Diagnostics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?